← Back to headlines
Pfizer-backed Priovant Wins FDA Priority Review for Lead Asset
Priovant, a company backed by Pfizer, has received FDA priority review for its lead asset, indicating a fast-tracked evaluation process for a new drug.
3 Mar, 12:24 — 3 Mar, 12:24
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
PH records 701,884 deaths in 2024; nearly half occur outside health facilities
just now
We’re asking the wrong question about exercise – it’s not about what’s best, but what sticks
20m ago
Évora Hospital pioneers AI use to detect cancer
25m ago
Stephanie Buttermore cause of death: What happened to Jeff Nippard's fiancé? Details
43m ago